Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2024 Dec 16;19(12):e0311124.
doi: 10.1371/journal.pone.0311124. eCollection 2024.

Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis

Masoumeh Beig  1 , Elnaz Parvizi  2 , Tahereh Navidifar  3 , Narjes Bostanghadiri  4 , Maryam Mofid  5 , Narges Golab  6 , Mohammad Sholeh  1   7
Affiliations
Meta-Analysis

Geographical mapping and temporal trends of Acinetobacter baumannii carbapenem resistance: A comprehensive meta-analysis

Masoumeh Beig et al. PLoS One. .

Erratum in

Abstract

Background: Carbapenem-resistant Acinetobacter baumannii (CRAB) is of critical concern in healthcare settings, leading to limited treatment options. In this study, we conducted a comprehensive meta-analysis to assess the prevalence of CRAB by examining temporal, geographic, and bias-related variations.

Methods: We systematically searched prominent databases, including Scopus, PubMed, Web of Science, and EMBASE. Quality assessment was performed using the JBI checklist. Subgroup analyses were performed based on the COVID-19 timeframes, years, countries, continents, and bias levels, antimicrobial susceptivity test method and guidelines.

Results: Our comprehensive meta-analysis, which included 795 studies across 80 countries from 1995 to 2023, revealed a surge in carbapenem resistance among A. baumannii, imipenem (76.1%), meropenem (73.5%), doripenem (73.0%), ertapenem (83.7%), and carbapenems (74.3%). Temporally, 2020-2023 witnessed significant peaks, particularly in carbapenems (81.0%) and meropenem (80.7%), as confirmed by meta-regression, indicating a steady upward trend.

Conclusion: This meta-analysis revealed an alarmingly high resistance rate to CRAB as a global challenge, emphasizing the urgent need for tailored interventions. Transparency, standardized methodologies, and collaboration are crucial for the accurate assessment and maintenance of carbapenem efficacy.

PubMed Disclaimer

Conflict of interest statement

The authors have declared that no competing interests exist.

Figures

Fig 1
Fig 1. PRISMA flow chart summarizes the article selection procedure.
Fig 2
Fig 2. Worldwide weighted pooled proportion of CRAB isolates.
Fig 3
Fig 3
Worldwide Map for Prevalence of CRAB; A: Imipenem, B: Meropenem, C: Doripenem, D: Ertapenem, and E: Carbapenem. Global map visualization created using OpenStreetMap data, available under the Open Database License (ODbL). Map data © OpenStreetMap contributors, licensed under ODbL.
Fig 4
Fig 4
Subgroup analysis results are illustrated as follows: A: Prevalence of CRAB isolates across continents; B: Compression prevalence of CRAB isolates according to different AST guidelines; C: Compression prevalence of CRAB isolates using various AST techniques; D: Compression prevalence of CRAB isolates according to the risk of bias in the JBI checklist results. E: Compression prevalence of CRAB isolates between year subgroups. F: Compression prevalence of CRAB isolates before and after the COVID-19 pandemic (1995–2019, and 2020–2023).
Fig 5
Fig 5
Meta regression of carbapenem resistance A. baumannii isolates during years; A: Imipenem, B: meropenem, C: Doripenem, D: Ertapenem E: carbapenem.
See this image and copyright information in PMC

References

    1. Abdul-Mutakabbir JC, Griffith NC, Shields RK, Tverdek FP, Escobar ZK. Contemporary perspective on the treatment of Acinetobacter baumannii infections: insights from the Society of Infectious Diseases Pharmacists. Infectious diseases and therapy. 2021:1–26. doi: 10.1007/s40121-021-00541-4 - DOI - PMC - PubMed
    1. Valentine SC, Contreras D, Tan S, Real LJ, Chu S, Xu HH. Phenotypic and molecular characterization of Acinetobacter baumannii clinical isolates from nosocomial outbreaks in Los Angeles County, California. Journal of clinical microbiology. 2008;46(8):2499–507. doi: 10.1128/JCM.00367-08 - DOI - PMC - PubMed
    1. Nguyen M, Joshi S. Carbapenem resistance in Acinetobacter baumannii, and their importance in hospital‐acquired infections: a scientific review. Journal of applied microbiology. 2021;131(6):2715–38. doi: 10.1111/jam.15130 - DOI - PubMed
    1. Jiang Y, Ding Y, Wei Y, Jian C, Liu J, Zeng Z. Carbapenem-resistant Acinetobacter baumannii: A challenge in the intensive care unit. Frontiers in microbiology. 2022;13:1045206. doi: 10.3389/fmicb.2022.1045206 - DOI - PMC - PubMed
    1. Shields RK, Paterson DL, Tamma PD. Navigating available treatment options for carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex infections. Clinical Infectious Diseases. 2023;76(Supplement_2):S179–S93. doi: 10.1093/cid/ciad094 - DOI - PMC - PubMed

Publication types

MeSH terms

LinkOut - more resources